# Veracyte, Inc.: overview

VCYT · Nasdaq · CIK 1384101 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vcyt.md) · [Financials](/companies/vcyt/financials.md) · [Filings](/companies/vcyt/filings.md) · [Insiders](/companies/vcyt/insiders.md)

Latest reported revenue: [$150.3m](/filings/0001384101-26-000044.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Jul 31, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001384101-26-000044).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [116](/filings/0001384101-25-000130.md) | [119 d](/filings/0001384101-26-000010.md) | [114](/filings/0001384101-26-000031.md) | [130](/filings/0001384101-26-000044.md) | [132](/filings/0001384101-25-000130.md) | [141 d](/filings/0001384101-26-000010.md) | [139](/filings/0001384101-26-000031.md) | [150](/filings/0001384101-26-000044.md) |
| Gross margin | % | [68.2%](/filings/0001384101-25-000130.md) | [66.4% d](/filings/0001384101-26-000010.md) | [69.5%](/filings/0001384101-26-000031.md) | [69.0%](/filings/0001384101-26-000044.md) | [69.2%](/filings/0001384101-25-000130.md) | [72.5% d](/filings/0001384101-26-000010.md) | [72.7%](/filings/0001384101-26-000031.md) | [72.2%](/filings/0001384101-26-000044.md) |
| Operating margin | % | [10.4%](/filings/0001384101-25-000130.md) | [3.5% d](/filings/0001384101-26-000010.md) | [2.5%](/filings/0001384101-26-000031.md) | [(4.0%)](/filings/0001384101-26-000044.md) | [17.4%](/filings/0001384101-25-000130.md) | [26.4% d](/filings/0001384101-26-000010.md) | [16.3%](/filings/0001384101-26-000031.md) | [15.3%](/filings/0001384101-26-000044.md) |
| Net margin | % | [13.1%](/filings/0001384101-25-000130.md) | [4.3% d](/filings/0001384101-26-000010.md) | [6.2%](/filings/0001384101-26-000031.md) | [(0.8%)](/filings/0001384101-26-000044.md) | [14.5%](/filings/0001384101-25-000130.md) | [29.3% d](/filings/0001384101-26-000010.md) | [20.6%](/filings/0001384101-26-000031.md) | [17.0%](/filings/0001384101-26-000044.md) |
| Diluted EPS | $ per share | [0.19](/filings/0001384101-25-000130.md) | not reported | [0.09](/filings/0001384101-26-000031.md) | [(0.01)](/filings/0001384101-26-000044.md) | [0.24](/filings/0001384101-25-000130.md) | not reported | [0.35](/filings/0001384101-26-000031.md) | [0.31](/filings/0001384101-26-000044.md) |
| Free cash flow | $m | [27.7 d](/filings/0001384101-25-000130.md) | [20.4 d](/filings/0001384101-26-000010.md) | [3.5](/filings/0001384101-26-000031.md) | [32.3 d](/filings/0001384101-26-000044.md) | [42.0 d](/filings/0001384101-25-000130.md) | [48.8 d](/filings/0001384101-26-000010.md) | [32.3](/filings/0001384101-26-000031.md) | [43.0 d](/filings/0001384101-26-000044.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [220](/filings/0001384101-24-000017.md) | [297](/filings/0001384101-25-000014.md) | [361](/filings/0001384101-26-000010.md) | [446](/filings/0001384101-26-000010.md) | [517](/filings/0001384101-26-000010.md) |
| Gross margin | % | not reported | [59.2%](/filings/0001384101-25-000014.md) | [63.6%](/filings/0001384101-26-000010.md) | [66.9%](/filings/0001384101-26-000010.md) | [70.1%](/filings/0001384101-26-000010.md) |
| Operating margin | % | [(37.3%)](/filings/0001384101-24-000017.md) | [(13.9%)](/filings/0001384101-25-000014.md) | [(23.8%)](/filings/0001384101-26-000010.md) | [3.6%](/filings/0001384101-26-000010.md) | [11.2%](/filings/0001384101-26-000010.md) |
| Net margin | % | [(34.4%)](/filings/0001384101-24-000017.md) | [(12.3%)](/filings/0001384101-25-000014.md) | [(20.6%)](/filings/0001384101-26-000010.md) | [5.4%](/filings/0001384101-26-000010.md) | [12.8%](/filings/0001384101-26-000010.md) |
| Diluted EPS | $ per share | [(1.11)](/filings/0001384101-24-000017.md) | [(0.51)](/filings/0001384101-25-000014.md) | [(1.02)](/filings/0001384101-26-000010.md) | [0.31](/filings/0001384101-26-000010.md) | [0.82](/filings/0001384101-26-000010.md) |
| Free cash flow | $m | [(37.0)](/filings/0001384101-24-000017.md) | [(1.0)](/filings/0001384101-25-000014.md) | [34.3](/filings/0001384101-26-000010.md) | [63.8](/filings/0001384101-26-000010.md) | [127](/filings/0001384101-26-000010.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Gross profit: us-gaap:GrossProfit.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/vcyt/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2026-10-27 | [Eastham Karin](/insiders/1231845.md) | Director | Sale (S) | 14,850 | $50.0049 | $742.6k | [Form 4](/filings/0001231845-26-000008.md) |
| 2026-10-27 | [Holstein Jens](/insiders/1819880.md) | Director | Sale (S) | 7,500 | $50.00 | $375.0k | [Form 4](/filings/0001819880-26-000006.md) |
| 2026-09-24 | [Holstein Jens](/insiders/1819880.md) | Director | Sale (S) | 7,500 | $47.00 | $352.5k | [Form 4](/filings/0001819880-26-000006.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $792.1m | 13,486,437 |  | Added +313,819 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $452.4m | 7,702,746 |  | Reduced −61,103 |
| [Artisan Partners Limited Partnership](/funds/1466153.md) | 2026-06-30 | $325.3m | 5,538,404 |  | Added +42,034 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $277.0m | 4,716,191 |  | Added +271,461 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $276.0m | 4,698,128 |  | Reduced −345,462 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $211.1m | 3,593,922 |  | Added +61,690 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $166.0m | 2,826,524 |  | Reduced −54,566 |
| [FIRST TRUST ADVISORS LP](/funds/1125816.md) | 2026-06-30 | $147.3m | 2,507,902 |  | Added +390,856 |
| [ARK Investment Management LLC](/funds/1697748.md) | 2026-06-30 | $134.8m | 2,295,951 |  | Reduced −757,867 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $133.6m | 2,274,160 |  | Reduced −284,125 |

## Recent filings

[All 1,162 filings](/companies/vcyt/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-14 | 16:07 ET | [8-K](/filings/0001384101-26-000049.md) | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001384101-26-000049 |
| 2026-07-31 | 16:11 ET | [10-Q](/filings/0001384101-26-000044.md) | Quarterly report, period 2026-06-30 | 0001384101-26-000044 |
| 2026-07-30 | 16:18 ET | [8-K](/filings/0001384101-26-000042.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001384101-26-000042 |
| 2026-06-11 | 16:32 ET | [8-K](/filings/0001384101-26-000038.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0001384101-26-000038 |
| 2026-05-06 | 08:07 ET | [10-Q](/filings/0001384101-26-000031.md) | Quarterly report, period 2026-03-31 | 0001384101-26-000031 |
| 2026-05-05 | 16:08 ET | [8-K](/filings/0001384101-26-000029.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001384101-26-000029 |
| 2026-04-22 | 16:06 ET | [DEF 14A](/filings/0001384101-26-000021.md) | Proxy statement, period 2026-06-10 | 0001384101-26-000021 |
| 2026-03-16 | 16:17 ET | [8-K](/filings/0001384101-26-000012.md) | 5.02 Departure or appointment of officers or directors | 0001384101-26-000012 |
| 2026-02-26 | 16:32 ET | [10-K](/filings/0001384101-26-000010.md) | Annual report, period 2025-12-31 | 0001384101-26-000010 |
| 2026-02-25 | 16:07 ET | [8-K](/filings/0001384101-26-000008.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001384101-26-000008 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001384101-26-000010.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/4a3f6472-478d-499a-a791-25796f6b8567)

## About the filer

- CIK: 1384101
- Tickers: VCYT
- Exchange: Nasdaq
- SIC code: 8071 Services-Medical Laboratories
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 16:51 ET. No prices; not investment advice.